A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C

Masanori Atsukawa, Akihito Tsubota, Chisa Kondo, Sawako Uchida-Kobayashi, Koichi Takaguchi, Akemi Tsutsui, Akito Nozaki, Makoto Chuma, Isao Hidaka, Tsuyoshi Ishikawa, Motoh lwasa, Yasuyuki Tamaig, Maki Tobari, Kentaro Matsuura, Yoshihito Nagura, Hiroshi Abe, Keizo Kato, Kent Suzuki, Tomomi Okubo, Taeang Arai, Norio Itokawa, Hidenori Toyoda, Masaru Enomoto, Akihira Tamori, Yasuhi To Nakad, Norifumi Kawada, Yoshiyuki Takei, Katsuhiro luki

1 Division of Gastroenterology and Hepatology, Nippon Medical School, Tokyo, Japan.
2 Core Research Facilities, The Jikei University School of Medicine, Tokyo, Japan.
3 Department of Hepatology, Graduate School of Medicine, Osaka City University, Osaka, Japan.
4 Department of Hepatology, Kagawa Prefectural Central Hospital, Kagawa, Japan.
5 Gastroenterological Center, Yokohama City University Medical Center, Kanagawa, Japan.
6 Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
7 Department of Gastroenterology and Hepatology, Mie University School of Medicine, Mie, Japan.
8 Department of Internal Medicine and Gastroenterology, Tokyo Women’s Medical University Yachiyo Medical Center, Chiba, Japan.
9 Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan.
10 Department of Internal Medicine, Division of Gastroenterology and Hepatology, Shimmatsudo Central General Hospital, Matsudo, Japan.
11 Department of Gastroenterology, Nippon Medical School Chiba Hokuso Hospital, Chiba, Chiba, Japan.
12 Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan.
13 Department of Gastroenterology and Hepatology, Kumamoto University, Kumamoto, Japan.

These authors contributed equally to this work.
* momogachi@yahoo.co.jp

Abstract

Evaluating liver fibrosis is crucial for disease severity assessment, treatment decisions, and hepatocarcinogenic risk prediction among patients with chronic hepatitis C. In this retrospective multicenter study, we aimed to construct a novel model formula to predict cirrhosis. A total of 749 patients were randomly allocated to training and validation sets at a ratio of 2:1. Liver stiffness measurement (LSM) was made via transient elastography using FibroScan. Patients with LSM \( \geq 12.5 \) kPa were regarded as having cirrhosis. The best model formula for predicting cirrhosis was constructed based on factors significantly and independently associated with LSM \( \geq 12.5 \) kPa using multivariate regression analysis. Among the 749 patients, 198 (26.4%) had LSM \( \geq 12.5 \) kPa. In the training set, multivariate analysis identified logarithm natural (ln) type IV collagen 7S, ln hyaluronic acid, and ln Wisteria floribunda agglutinin positive Mac-2-binding protein (WFA\(^{-}\)-Mac-2 BP) as the factors that were significantly and independently associated with LSM \( \geq 12.5 \) kPa. Thus, the formula was constructed as follows: score = \(-6.154 + 1.166 \times \text{ln type IV collagen 7S} + 0.526 \times \text{ln hyaluronic acid} + 1.069 \times \text{WFA\(^{-}\)-Mac-2 BP}\). The novel formula yielded the highest area under the curve (0.882; optimal cutoff, \(-0.381\)), specificity (81.5%), positive predictive values (62.6%), and predictive accuracy (81.6%) for predicting LSM \( \geq 12.5 \) kPa among fibrosis markers and indices. These results were almost similar to those in the validated set, indicating the reproducibility and validity of the novel formula. The novel formula scores were significantly, strongly, and positively correlated with LSM values in both the training and validation sets.
data sets (correlation coefficient, 0.721 and 0.762; \( p = 2.67 \times 10^{-81} \) and \( 1.88 \times 10^{-48} \), respectively). In conclusion, the novel formula was highly capable of diagnosing cirrhosis in patients with chronic hepatitis C and exhibited better diagnostic performance compared to conventional fibrosis markers and indices.

**Introduction**

Liver fibrosis evaluation is crucial for determining liver disease severity, planning treatment strategies, and predicting hepatocarcinogenic risk among patients with chronic hepatitis C. Despite being the gold standard for liver fibrosis staging, liver biopsy is a time-consuming, labor-intensive, and invasive procedure with some limitations, such as sampling errors and nonacceptability to repeated examinations. Alternatively, various noninvasive methods, such as serologic fibrosis markers/formulae and tissue elasticity measurements via ultrasonography and magnetic resonance imaging, overcome the drawbacks of liver biopsy or render it unnecessary and can be useful in estimating the severity of liver fibrosis and detecting cirrhosis [1–17].

Conventional hematologic and serologic fibrosis markers routinely used include platelet count [2], type IV collagen 7S [3, 4], type III procollagen N-terminal peptide (P-III-P) [4–6], and hyaluronic acid [7]. Moreover, Wisteria floribunda agglutinin–Mac-2 binding protein (WFA+–M2BP) has recently been established as a valuable serologic fibrosis marker in Japan [8, 9]. WFA+–M2BP has been found to be useful for diagnosing patients with advanced fibrosis due to chronic hepatitis B and non-alcoholic fatty liver disease, as well as chronic hepatitis C [9, 11, 12], and is superior to other conventional fibrosis markers [10]. Apart from these single serologic markers, several scoring systems comprising a combination of multiple laboratory tests, such as aspartate aminotransferase to platelet ratio index (APRI) [13], fibrosis-4 (FIB-4) index [14], and FibroTest [15], have been proposed for estimating liver fibrosis.

Alternatively, studies have suggested the usefulness of elastography for noninvasively evaluating liver fibrosis [16, 17]. Elastography is a liver stiffness calculation method in which liver hardness is measured by observing sound waves, such as shear waves, and the transmission of shear waves and vibration within the liver in response to external physical vibration. The representative method includes ultrasound elastography in which liver stiffness is measured using ultrasound waves. In practice, liver stiffness measurement (LSM) via ultrasound elastography can be utilized as a risk indicator for hepatocellular carcinoma in patients with untreated chronic hepatitis C [18]. However, some problems, such as influence of liver inflammation on liver stiffness and different cutoff values according to the etiology of liver diseases [19–21], have remained a concern. Several studies have sought to determine the optimal cutoff value of ultrasound elastography for chronic hepatitis C. In a study involving 251 patients, the cutoff value of LSM for predicting cirrhosis was 14.6 kilopascals (kPa) [16]. According to another study involving 186 patients, the cutoff value of LSM for predicting cirrhosis was 12.5 kPa, which was equivalent to the findings of APRI and FibroTest [17]. Recent major phase 3 trials on interferon-free direct-acting antivirals (DAAs) for chronic hepatitis C had utilized transient elastography via FibroScan as an alternative method for liver biopsy to assess liver fibrosis, adopting LSM \( \geq 12.5 \text{ kPa} \) as the criterion for the diagnosis of cirrhosis [22–24]. However, not all facilities can install this expensive equipment. Therefore, a novel fibrosis marker or index capable of noninvasively and conveniently diagnosing cirrhosis (equivalent to LSM \( \geq 12.5 \text{ kPa} \)) without special equipment is urgently needed.
This multicenter study aimed to construct a novel model formula to noninvasively and simply predict cirrhosis among patients with chronic hepatitis C.

**Materials and methods**

**Subjects**

A total of 749 consecutive patients who were diagnosed with chronic hepatitis C and underwent transient elastography (FibroScan, Echosens, Paris, France) at Nippon Medical School Chiba Hokusoh Hospital, Nippon Medical School, Tokyo Women’s Medical University Yachiyo Medical Center, Mie University School of Medicine, Yamaguchi University Graduate School of Medicine, Yokohama City University Medical Center, Shinmatsu Central General Hospital, Nagoya City University, Kagawa Prefectural Central Hospital, and Osaka City University Medical School from April 2014 to June 2020 were included in this retrospective study. The inclusion criteria were as follows: (1) persistent presence of serum hepatitis C virus (HCV) RNA; (2) chronic liver disease diagnosed based on laboratory, histology, and/or imaging tests, including ultrasonography and computed tomography; and (3) available data on serologic fibrosis markers and transient elastography. Patients complicated by other chronic liver diseases (such as chronic hepatitis B, autoimmune hepatitis, and primary biliary cholangitis) were excluded. Patients with severe obesity or massive ascites were also excluded because shear waves and vibration are difficult to propagate to the liver when performing transient elastography for such patients. The 749 patients were randomly allocated to training and validation sets at a ratio of 2:1 (500 and 249 patients, respectively; Table 1). This study was conducted in accordance with the ethical guidelines established in the 2013 Helsinki Declaration and was approved by the ethics committee of Nippon Medical School Hokusoh Hospital (approval No. 675–2). After obtaining written informed consent, serum samples from the patients were collected and stored for measuring some serum markers. All data at each institution were completely anonymized. The ethics committee waived the requirement for informed consent in this retrospective study. The patients were given the option to abstain from participating in this study.

**Transient elastography**

LSM was made via transient elastography using FibroScan [16], which is covered under medical insurance and routinely performed to evaluate the degree of liver fibrosis in patients with chronic liver disease in Japan. This system was equipped with a probe that includes an ultrasonic transducer mounted on the axis of a vibrator. A mild amplitude and low frequency vibration were transmitted from the vibrator toward the tissue by the transducer itself. This vibration induced an elastic shear wave that propagates through the tissue. Meanwhile, pulse-echo ultrasound images were acquired to follow the propagation of the shear wave and measure its velocity, which was directly related to tissue stiffness (or elastic modulus). Measurement results were expressed as kPa, with harder tissues having faster shear wave propagation. Measurements were performed on the right lobe of the liver through the intercostal spaces while the patient was lying in the dorsal decubitus position with the right arm in maximal abduction. The tip of the transducer probe was covered with coupling gel and placed on the skin between the ribs on the right lobe of the liver. The operator, assisted by time-motion and A-mode ultrasound images provided by the system, located a portion of the liver that was at least 6 cm thick and had no large vascular structures. Once the target measurement area had been located, the operator pressed the probe button to start the measurements. The measurement depth was between 25 and 45 mm from the liver surface. Ten successful measurements were performed on each patient, with the success rate being calculated as the ratio of the
number of successful measurements over the total number of measurements. The median value was determined as a representative of the liver elastic modulus. The entire examination lasted less than 5 minutes. Only LSM obtained after 10 successful procedures, a success rate of at least 60%, and an interquartile range to median value ratio of less than 30% were considered reliable. The median value of successful measurements was determined as representative of LSM. Based on the elastography findings, patients with LSM $\geq 12.5$ kPa were regarded as having cirrhosis (METAVIR fibrosis stage F4) [17].

### Fibrosis markers and formulae

Laboratory test results for the following fibrosis markers were collected from the medical records within at least 3 months from the date of transient elastography measurement: platelet count, type IV collagen 7S, hyaluronic acid, P-III-P, and WFA$^+$-M2BP. Missing data on these tests were retrospectively measured using frozen stored sera. Serum WFA$^+$-M2BP levels were measured using a sandwich enzyme-linked immunosorbent assay with lectin (WFA)-recognizing carbohydrate chains, including altered N-acetylgalactosamine (HISCL-2000i, Sysmex, Hyogo, Japan), which were standardized and converted to a cutoff index (COI) according to the manufacture's specified formula [9]. APRI was calculated as follows: $\frac{\text{AST (U/L)}}{\text{AST upper limit of normal (U/L)}} \times \frac{\text{platelet count (}\times 10^9/L\text{)}}{100}$ [13], FIB-4 index was calculated as follows: $\frac{\text{age (year)} \times \text{AST (U/L)}}{\text{platelet count (}\times 10^9/L\text{)} \times \text{ALT (U/L)}^{1/2}}$ [14].

| Variable                                      | Training set | Validation set | p value |
|-----------------------------------------------|--------------|----------------|---------|
| Gender (Male/ Female)                         | N = 500      | N = 249        | 0.140   |
| Age (years)                                   | 260 / 240    | 144 / 105      | 0.051   |
| History of antiviral therapy                  | 67 (26–90)   | 67 (26–88)     | 0.514   |
| History of hepatocellular carcinoma (presence/absence) | 77 / 59 / 364 | 36 / 27 / 186  | 0.591   |
| Platelet count ($\times 10^3$/mm$^3$)         | 164 (27–453) | 167 (25–404)   | 0.770   |
| AST (U/L)                                     | 39 (10–410)  | 37 (4–233)     | 0.382   |
| ALT (U/L)                                     | 35 (3–445)   | 33 (5–299)     | 0.356   |
| Serum albumin (g/dL)                          | 4.1 (2.0–5.2) | 4.1 (2.1–4.7) | 0.499   |
| Total Bilirubin (mg/dL)                       | 0.6 (0.2–8.0) | 0.6 (0.1–3.4) | 0.713   |
| Type IV collagen 7S (ng/mL)                   | 4.9 (1.9–1880.0) | 5.1 (2.1–971.0) | 0.696   |
| <5.6 ng/mL / $\geq$5.6 ng/mL                  | 298 / 202    | 138 / 111      | 0.307   |
| Hyaluronic acid (ng/mL)                       | 83.2 (1.5–3015.8) | 108.5 (5.0–1812.2) | 0.129   |
| <140.4 ng/mL / $\geq$140.4 ng/mL              | 322 / 178    | 151 / 98       | 0.335   |
| WFA$^+$-M2BP (COI)                            | 1.93 (0.22–20.00) | 1.84 (0.33–17.94) | 0.797   |
| <2.67 COI / $\geq$2.67 COI                    | 308 / 192    | 165 / 84       | 0.228   |
| FIB-4 index                                   | 2.72 (0.33–23.27) | 2.76 (0.18–18.62) | 0.655   |
| <3.74 / $\geq$3.74                           | 320 / 180    | 164 / 85       | 0.628   |
| APRI                                          | 0.66 (0.11–12.53) | 0.58 (0.04–6.70) | 0.415   |
| <0.70 / $\geq$0.70                           | 265 / 235    | 145 / 104      | 0.186   |
| LSM (kPa)                                     | 7.8 (1.1–23.3) | 7.9 (2.6–75.0) | 0.655   |
| <12.5 / $\geq$12.5 kPa                       | 363 / 137    | 188 / 61       | 0.429   |

Categoric values are given as number. Continuous variables are given as median (range).

AST, aspartate aminotransferase; ALT, alanine aminotransferase; WFA$^+$-M2BP, Wisteria floribunda agglutinin positive Mac-2-binding protein; COI, cutoff index, FIB-4 index, fibrosis-4 index; APRI, aspartate aminotransferase to platelet ratio index; LSM, liver stiffness measurement.

https://doi.org/10.1371/journal.pone.0257166.t001
Statistical analyses

To compare the clinical characteristics between the training and validation sets, the Mann–Whitney U test and Fisher exact test for continuous and categorical variables, respectively, were used. First, the following variables were included in the univariate analysis of the training set: age, platelet count, type IV collagen 7S, hyaluronic acid, and WFA$$^-$$-M2BP. When continuous variables were right-skewed, natural logarithmic transformations of the original data were applied to reduce the skewness of the distribution. Subsequently, factors determined as significant on univariate analysis were entered into multiple logistic regression analysis to identify those independently associated with LSM $$\geq 12.5$$ kPa (cirrhosis). The best model formula for predicting cirrhosis was then constructed based on the final-step results. A two-sided p value of $$<0.05$$ was considered statistically significant. The optimal cutoff values of variables and formulae for predicting cirrhosis were assessed using receiver operating characteristic (ROC) analysis and were determined using the Youden index. The DeLong’s test was used to compare the area under the curve (AUC) values between the novel formula and conventional fibrosis markers. Sensitivity, specificity, and positive and negative predictive values (PPV and NPV) were also calculated based on the optimal cutoff values determined. To analyze the correlation between LSM and scores calculated from the formula constructed in the training set, Spearman’s rank correlation coefficient was calculated using the validation set. Statistical analyses were performed using BellCurve for Excel (Social Survey Research Information, Tokyo, Japan).

Results

Patient characteristics

Among the 749 patients included in this retrospective study [median age of 67 years (range, 26–90 years)], 404 were men and 345 were women, while 198 (26.4%) had LSM $$\geq 12.5$$ kPa (cirrhosis). The 749 patients were randomly allocated to the training (n = 500) and validation (n = 249) sets, with no significant differences in baseline characteristics between both sets (Table 1).

Analyses of factors associated with LSM $$\geq 12.5$$ kPa (cirrhosis)

The optimal cutoff values of conventional serologic markers for predicting LSM $$\geq 12.5$$ kPa in the training set were determined using ROC curve analysis. Accordingly, the optimal cutoff and AUC values were 5.6 ng/mL and 0.851 for type IV collagen 7S, 140.4 ng/mL and 0.768 for hyaluronic acid, and 2.67 COI and 0.851 for WFA$$^-$$-M2BP, respectively (Fig 1), with type IV collagen 7S and WFA$$^-$$-M2BP showing the highest AUC for predicting LSM $$\geq 12.5$$ kPa.

Univariate and multivariate analyses identified the following three factors as significantly and independently associated with LSM $$\geq 12.5$$ kPa: logarithm natural (ln) type IV collagen 7S [odds ratio (OR) = 3.210, p = $$1.09 \times 10^{-7}$$], ln hyaluronic acid (OR = 1.692, p = $$4.25 \times 10^{-4}$$), and ln WFA$$^-$$-M2BP (OR = 2.913, p = $$3.63 \times 10^{-5}$$) (Table 2). Thus, the following formula for predicting LSM $$\geq 12.5$$ kPa was constructed: score = $$-6.154 + 1.166 \times$$ ln type IV collagen 7S + $$0.526 \times$$ ln hyaluronic acid + $$1.069 \times$$ WFA$$^-$$-M2BP. A comparison of the diagnostic performance between the novel formula and conventional fibrosis indices revealed the optimal cutoff and AUC values of 3.74 and 0.795 for FIB-4 index, 0.70 and 0.809 for APRI, and $$-0.381$$ and 0.882 for the novel formula, respectively (Fig 2). Among these fibrosis indices, the novel formula offered the highest AUC (0.882) for predicting LSM $$\geq 12.5$$ kPa. Type IV collagen 7S and WFA$$^-$$-M2BP generated the second highest AUC (0.851 for both). On comparing these AUC values, it was revealed that the novel formula offered a significantly greater AUC than type IV
collagen 7S ($p = 0.022$) and WFA$^+$-M2BP ($p = 4.52 \times 10^{-3}$), suggesting superior accuracy of the novel formula for predicting LSM $\geq 12.5$ kPa (cirrhosis). The novel formula yielded the highest specificity (81.5%), PPV (62.6%), and predictive accuracy (81.6%); the second highest NPV (92.2%); and the third highest sensitivity (81.8%) for predicting LSM $\geq 12.5$ kPa among the aforementioned fibrosis markers and indices (Table 3). Analysis of the correlation between LSM values and the novel formula scores showed a correlation coefficient of 0.721 ($p = 2.67 \times 10^{-81}$), indicating a significant, strong, and positive correlation (Fig 3A).

Table 2. Analysis of factors associated with liver stiffness measurement $\geq 12.5$ kPa (liver cirrhosis).

| Variable                      | Category          | Univariate                  | Multivariate                |
|-------------------------------|-------------------|-----------------------------|----------------------------|
| Age (years)                   | 1 year up         | OR 1.034 95% CI 1.016–1.053 | OR 1.83 $\times 10^{-4}$   |
| Platelet count ($\times 10^{3}/\text{mm}^3$) | 1.0 $\times 10^{3}/\text{mm}^3$ down | OR 1.199 95% CI 1.149–1.252 | OR 1.38 $\times 10^{-16}$  |
| AST (U/L)                     | 1 U/L up          | OR 1.015 95% CI 1.010–1.021 | OR 4.81 $\times 10^{-8}$   |
| ALT (U/L)                     | 1 U/L up          | OR 1.008 95% CI 1.004–1.012 | OR 1.14 $\times 10^{-4}$   |
| Serum albumin (g/dL)         | 1 g/dL down       | OR 8.601 95% CI 4.924–15.024 | OR 3.97 $\times 10^{-14}$  |
| Total Bilirubin (mg/dL)       | 1.0 mg/mL up      | OR 3.358 95% CI 1.844–6.116 | OR 7.49 $\times 10^{-5}$   |
| ln type IV collagen 7S (ng/mL)| 1.0 ng/mL up      | OR 5.562 95% CI 3.370–9.183 | OR 1.95 $\times 10^{-11}$  |
| ln hyaluronic acid (ng/mL)    | 1.0 ng/mL up      | OR 2.162 95% CI 1.784–2.619 | OR 3.41 $\times 10^{-15}$  |
| ln WFA$^+$-M2BP (COI)         | 1.0 COI up        | OR 5.718 95% CI 4.098–7.980 | OR 1.13 $\times 10^{-24}$  |

In, logarithm natural; OR, odds ratio; 95% CI, 95% confidential interval; WFA$^+$-M2BP, Wisteria floribunda agglutinin positive Mac-2-binding protein; COI, cutoff index.
Fig 2. Receiver operating characteristic curve analysis of each fibrosis formula for predicting cirrhosis in the training set. FIB-4 index, fibrosis-4 index; APRI, aspartate aminotransferase to platelet ratio index.

https://doi.org/10.1371/journal.pone.0257166.g002

Table 3. Diagnostic performance of fibrosis markers and formulae for predicting LSM ≥12.5 kPa (liver cirrhosis) in the training set.

| Factors                          | LSM ≥12.5 kPa (n = 137) | LSM <12.5 kPa (n = 363) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Predictive accuracy (%) |
|----------------------------------|-------------------------|-------------------------|-----------------|-----------------|---------|---------|-------------------------|
| Type IV collagen 7S ≥5.6 ng/mL   | 113                     | 89                      | 82.5            | 75.5            | 55.9    | 91.9    | 77.4                    |
| Type IV collagen 7S <5.6 ng/mL   | 24                      | 274                     |                 |                 |         |         |                         |
| Hyaluronic acid ≥140.4 ng/mL     | 100                     | 78                      | 73.0            | 78.5            | 56.2    | 88.5    | 77.0                    |
| Hyaluronic acid <140.4 ng/mL     | 37                      | 285                     |                 |                 |         |         |                         |
| WFA⁺-M2BP ≥2.67 COI              | 111                     | 81                      | 81.0            | 77.7            | 57.8    | 91.6    | 78.6                    |
| WFA⁺-M2BP <2.67 COI              | 26                      | 282                     |                 |                 |         |         |                         |
| FIB-4 index ≥3.74                | 99                      | 81                      | 72.3            | 77.7            | 55.0    | 88.1    | 76.2                    |
| FIB-4 index <3.74                | 38                      | 282                     |                 |                 |         |         |                         |
| APRI ≥0.70                       | 118                     | 117                     | 86.1            | 67.8            | 50.2    | 92.8    | 72.8                    |
| APRI <0.70                       | 19                      | 246                     |                 |                 |         |         |                         |
| New formula ≥−0.381              | 112                     | 67                      | 81.8            | 81.5            | 62.6    | 92.2    | 81.6                    |
| New formula < −0.381             | 25                      | 296                     |                 |                 |         |         |                         |

LSM, liver stiffness measurement; FIB-4 index, fibrosis-4 index; WFA⁺-M2BP, Wisteria floribunda agglutinin⁺—Mac-2 binding protein; COI, cutoff index; APRI, aspartate aminotransferase to platelet ratio index; PPV, positive predictive value; NPV, negative predictive value.

https://doi.org/10.1371/journal.pone.0257166.t003

https://doi.org/10.1371/journal.pone.0257166.t003
Validation study

The aforementioned training set results were validated using the validation set. Among these fibrosis markers and indices, the novel formula yielded the highest specificity (81.9%), PPV (60.9%), NPV (95.1%), and predictive accuracy (83.1%); and the second highest sensitivity (86.9%) for predicting LSM $\geq 12.5$ kPa (Table 4). Analysis of the correlation between LSM values and the novel formula scores revealed a correlation coefficient of 0.762 ($p = 1.88 \times 10^{-48}$), indicating a significant, strong, and positive correlation (Fig 3). AUC values were 0.898, 0.876, 0.868, 0.814, 0.784, and 0.754 for the novel formula, WFA$^+$-M2BP, type IV collagen 7S, FIB-4 index, APRI, and hyaluronic acid, respectively, indicating that they were almost similar to those in the training set. The novel formula offered the highest AUC both in the validation and training sets, although differences were not statistically significant (novel formula versus

Table 4. Diagnostic performance of fibrosis markers and formulae for predicting LSM $\geq 12.5$ kPa (liver cirrhosis) in the validation set.

| Factors                        | LSM $\geq 12.5$ kPa (n = 61) | LSM $< 12.5$ kPa (n = 188) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Predictive accuracy (%) |
|--------------------------------|-------------------------------|----------------------------|-----------------|-----------------|---------|---------|------------------------|
| Type IV collagen 7S $\geq 5.6$ ng/mL | 54                           | 57                         | 88.5            | 69.7            | 48.6    | 94.9    | 74.3                   |
| Type IV collagen 7S $< 5.6$ ng/mL   | 7                            | 131                        |                 |                 |         |         |                        |
| Hyaluronic acid $\geq 140.4$ ng/mL | 45                           | 53                         | 73.8            | 71.8            | 45.9    | 89.4    | 72.3                   |
| Hyaluronic acid $< 140.4$ ng/mL     | 16                           | 135                        |                 |                 |         |         |                        |
| WFA$^+$-M2BP $\geq 2.67$ COI        | 48                           | 36                         | 78.7            | 80.9            | 57.1    | 92.1    | 80.3                   |
| WFA$^+$-M2BP $< 2.67$ COI           | 13                           | 152                        |                 |                 |         |         |                        |
| FIB-4 index $\geq 3.74$             | 44                           | 41                         | 72.1            | 78.2            | 51.8    | 89.6    | 76.7                   |
| FIB-4 index $< 3.74$                | 17                           | 147                        |                 |                 |         |         |                        |
| APRI $\geq 0.70$                   | 47                           | 57                         | 77.0            | 69.7            | 45.2    | 90.3    | 71.5                   |
| APRI $< 0.70$                      | 14                           | 131                        |                 |                 |         |         |                        |
| New formula $\geq -0.381$           | 53                           | 34                         | 86.9            | 81.9            | 60.9    | 95.1    | 83.1                   |
| New formula $< -0.381$              | 8                            | 154                        |                 |                 |         |         |                        |

LSM, liver stiffness measurement; FIB-4 index, fibrosis-4 index; WFA$^+$-M2BP, Wisteria floribunda agglutinin$^+$—Mac-2 binding protein; COI, cutoff index; APRI, aspartate aminotransferase to platelet ratio index; PPV, positive predictive value; NPV, negative predictive value.

https://doi.org/10.1371/journal.pone.0257166.t004
Score distribution of the novel formula

Fig 4 shows the distribution of scores calculated using the novel formula in training set patients with LSM < 12.5 kPa and ≥ 12.5 kPa. Accordingly, the median values were −1.540 (interquartile range, −2.535 to −0.671) and 1.270 (interquartile range, −0.223 to 2.384) in patients with LSM < 12.5 kPa and ≥ 12.5 kPa, respectively (p = 6.10 × 10^{−15}). Therefore, the optimal cutoff value of −0.381 for the novel formula could discriminate between patients with and without cirrhosis.

Discussion

Since 2014, DAAs have become the mainstream treatment for patients with chronic hepatitis C [25] and have been considered effective and safe for not only compensated but also decompensated cirrhosis [26–30]. There are two reasons for why accurate cirrhosis diagnosis is imperative: (1) decisions on the optimal DAA treatment regimen for cirrhosis and (2) identification of cirrhosis with high hepatocarcinogenic risk. Our previous work reported that the presence of cirrhosis attenuated the efficacy of DAAs [31]. In 2020, the European Association for the Study of Liver guidelines recommend an 8-week administration of glecaprevir/pibrentasvir for DAA-naive patients regardless of whether cirrhosis was present [32]. Meanwhile, The Japan Society of Hepatology guidelines recommend an 8- and 12-week administration of glecaprevir/pibrentasvir for patients without and with cirrhosis, respectively [33]. Therefore, it
is important to discriminate between patients with and without cirrhosis in the treatment of chronic hepatitis C. However, the Asian Pacific Association for the Study of the Liver guidelines state that liver biopsy is not always recommended for diagnostic purposes or guiding treatment decisions [34]. Given that patients with cirrhosis have a high risk for developing hepatocellular carcinoma even long after HCV elimination [35–38], a simple noninvasive procedure for detecting cirrhosis is convenient and crucial for establishing a medication schedule in clinical practice.

This study constructed a model for predicting cirrhosis among patients with chronic hepatitis C and verified its diagnostic performance using a validation data set. The novel formula yielded the highest specificity, PPV, NPV, predictive accuracy, and AUC among the fibrosis markers and indices analyzed in both the training and validation data sets. The sensitivity of the novel formula was third highest in the training set and second highest in the validation set. In contrast, no other markers/indices showed results as stable as that of the novel formula. Accordingly, our results demonstrated that the novel formula was highly capable of diagnosing cirrhosis and superior to single serologic markers (type IV collagen 7S, hyaluronic acid, and WFA⁺-M2BP) and fibrosis indices (FIB-4 index and APRI) used widely in clinical practice. Notably, scores calculated using the novel formula had a significant, positive, and strong correlation with LSM values and clearly distinguished between patients with LSM ≥12.5 kPa (cirrhosis) and <12.5 kPa (non-cirrhosis).

FibroScan is an extremely useful tool for estimating the degree of liver fibrosis. However, not all facilities can install this expensive equipment. The simplicity and convenience of conventional fibrosis markers, such as platelet count, type IV collagen 7S, hyaluronic acid, and WFA⁺-M2BP, have certainly facilitated their use. Platelet count decreases with cirrhosis progression in patients with chronic hepatitis C [2]. Type IV collagen constitutes the hepatic sinusoidal basement membrane and increases with basement membrane hyperplasia accompanied by liver fibrosis progression [3], while type IV collagen 7S is the N-terminal 7S region of type IV collagen and behaves quite similarly thereto. However, given that collagen is distributed throughout the body and is not limited to the liver, increased serum levels of type IV collagen and type IV collagen 7S have been observed in collagen disease, renal disease, and pulmonary fibrosis and do not specifically reflect the extent of liver fibrosis [4]. Hyaluronic acid is mainly produced in fibroblasts, stellate cells, and synovial cells and distributed throughout connective tissue. Although it is normally present in very small amounts in serum, serum levels thereof become elevated when stellate cell production is promoted, liver fibrosis progresses, and incorporation into sinusoidal endothelial cells decreases [7]. Hyaluronic acid can be particularly useful for differentiating between patients with and without cirrhosis; however, it also correlates with inflammation. Therefore, when evaluating liver fibrosis using hyaluronic acid, the degree of inflammation should be carefully considered [7].

APRI and FIB-4 index, the scoring systems exclusively used for patients with chronic hepatitis C, are calculated using formulae including AST, ALT, and platelet count, which are readily available during routine clinical practice [13, 14] but can be susceptible to the degree of liver inflammation. In fact, these index values improve shortly after HCV elimination and biochemical normalization with DAAAs. However, liver fibrosis improves over years after HCV elimination, whereas hepatic necroinflammation disappears relatively quickly [39]. Similarly, serum WFA⁺-M2BP levels rapidly decline after HCV elimination, suggesting the influence of liver inflammation. Given that the formula for FIB-4 index involves an age component, the degree of liver fibrosis may be overestimated in elderly patients. In contrast, the novel formula does not include AST, ALT, and age, suggesting minimal influence of liver inflammation and aging.

This study has some limitations. First, the retrospective nature of this study was a major limitation. Second, a considerable number of participants including herein did not undergo
liver biopsy, with only 57 patients undergoing liver biopsy. Among them, four patients were diagnosed with cirrhosis following liver biopsy, and all had LSM ≥12.5 kPa, which was the cut-off value for diagnosing cirrhosis in previous studies [17]. Nowadays, performing liver biopsy for the sole purpose of grading necroinflammation and staging fibrosis in patients with chronic hepatitis C is unrealistic given its highly invasive and risky nature, especially among those with cirrhosis. Alternatively, although several noninvasive serologic markers and formulæ for liver fibrosis staging are available in clinical practice, they have been developed based on histopathological fibrosis staging from liver biopsy specimens. The novel formula for predicting liver fibrosis constructed herein was based on cirrhosis diagnosis established using LSM values obtained via FibroScan. However, the novel formula may be relatively complex, with all constituting components being fibrosis markers that may be less common than conventional fibrosis indices, such as APRI and FIB-4 index. Moreover, we did not evaluate changes in the novel formula scores after DAA treatment. In the future, our ground is willing to investigate the correlation between changes in scores and prognosis, especially among patients with cirrhosis receiving DAA treatment.

In conclusion, this study validated the ability of the novel formula constructed herein for predicting cirrhosis in patients with chronic hepatitis C. Accordingly, the novel formula yielded scores that were well correlated with LSM on FibroScan and exhibited better diagnostic performance for predicting cirrhosis compared to conventional markers and indices. Further studies are needed to confirm the usefulness of this novel formula in detecting patients with cirrhosis and identifying those with a high hepatocarcinogenic risk after eliminating HCV with DAAs treatment.

Supporting information
S1 Data.
(XLSX)

Acknowledgments
The authors wish to thank all medical doctors from all institutions who were involved in this study.

Author Contributions
Conceptualization: Masanori Atsukawa, Hidenori Toyoda.
Data curation: Masanori Atsukawa, Chisa Kondo, Sawako Uchida-Kobayashi, Koichi Takaguchi, Akemi Tsutsui, Akito Nozaki, Makoto Chuma, Isao Hidaka, Tsuyoshi Ishikawa, Motoh Iwasa, Yasuyuki Tamai, Maki Tobari, Kentaro Matsuura, Yoshihito Nagura, Hiroshi Abe, Keizo Kato, Kenta Suzuki, Tomomi Okubo, Taeang Arai, Norio Itokawa, Masaru Enomoto, Akihiro Tamori, Yasuhiro Tanaka, Norifumi Kawada, Yoshiyuki Takei.
Formal analysis: Chisa Kondo.
Methodology: Masanori Atsukawa.
Project administration: Masanori Atsukawa.
Supervision: Akihito Tsubota, Katsuhiko Iwakiri.
Writing – original draft: Masanori Atsukawa.
Writing – review & editing: Akihito Tsubota.
References

1. Singh S, Muir AJ, Dieterich DT, Falck-Ytter YT. American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases. Gastroenterology. 2017; 152:1544–1577. https://doi.org/10.1053/j.gastro.2017.03.016 PMID: 28442120

2. Ono E, Shiratori Y, Okudaira T, Imamura M, Teratani T, Kanai F, et al. Platelet count reflects stage of chronic hepatitis C. Hepatol Res. 1998; 15:192–200. https://doi.org/10.1016/S1386-6536(98)00075-8

3. Hahn E, Wick G, Pencov D, Timpl R. Distribution of basement membrane proteins in normal and fibrotic human liver: collagen type IV, laminin, and fibronectin. Gut. 1980; 21:63–71. https://doi.org/10.1136/gut.21.1.63 PMID: 6983303

4. Murawaki Y, Ikuta J, Koda M, et al. Serum type III procollagen peptide, type IV collagen 7S domain, central triple-helix. Hepatology. 1994; 20:780–787. https://doi.org/10.1002/hep.1840200403 PMID: 7927217

5. Herslev-Petersen K, Kim KY, Pedersen LR, Bentsen KD, Uldbjerg N, Oxlund H, et al. Serum amino-terminal type III procollagen peptide: relation to biosynthesis of collagen type III in experimental induced granulaine tissue in rats. Acta Pathol Microbiol Immunol Scand. 1988; 96:793–804. PMID: 3048338

6. Herslev-Petersen K, Pedersen LR, Bentsen KD, Garbarsch C, Kim KY, Hahn EG, et al. Collagen type IV and procollagen type III during granulaine tissue formation. Eur J Clin Invest. 1988; 6:752 https://doi.org/10.1011/j.j.1935-2362.1988.tb01023.x PMID: 3139420

7. Laurent TC, Laurent UB, Fraser JR. Serum hyaluronan as a disease marker. Ann Med. 1996; 28:241–253. https://doi.org/10.3109/07853999609033126 PMID: 8811168

8. Kuno A, Ikehara Y, Tanaka Y, Ito K, Matsuda A, Sekiya S, et al. A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep. 2013; 3:1065. https://doi.org/10.1038/srep01065 PMID: 2323209

9. Yamasaki K, Tateyama M, Abiru S, Komori A, Nagaoka S, Saei K, et al. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in patients with hepatitis C patients. Hepatology. 2014; 60:1563–1570. https://doi.org/10.1002/hep.27305 PMID: 25042054

10. Abe M, Miyake T, Kuno A, Imai Y, Sawai Y, Hino K, et al. Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol. 2015; 50:776–784. https://doi.org/10.1007/s00535-014-1007-2 PMID: 25326152

11. Ichikawa Y, Joshi TA, Umemura T, Shibugawa Y, Usami Y, Shibata S, et al. Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in patients with chronic hepatitis B Virus infection. Hepatol Res. 2017; 47:226–233. https://doi.org/10.1111/hepr.12712 PMID: 27029022

12. Nishikawa H, Enomoto H, Iwata Y, Kishino K, Shimonou Y, Hasegawa K, et al. Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2 binding protein level in non-alcoholic steatohepatitis. Hepatol Res. 2016; 46:1194–1200. https://doi.org/10.1111/hepr.12662 PMID: 26836229

13. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeeraram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003; 38:518–526. https://doi.org/10.1053/jhep.2003.50346 PMID: 12883497

14. Valet-Phichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. Fib-4: an inexpensive and accurate marker of fibrosis in HCV infection, comparison with liver biopsy and fibrotest. Hepatology. 2007; 46:32–36. https://doi.org/10.1002/hep.21669 PMID: 17567829

15. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poyrand T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infections: a prospective study. Lancet. 2001; 357:1069–1075. https://doi.org/10.1016/S0140-6736(00)04258-6 PMID: 11297957

16. Ziol M, Handra-Luca A, Kettanhe A, Christidis C, Mal F, Kazemi F, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology. 2005; 41:48–54. https://doi.org/10.1002/hep.20506 PMID: 15690481

17. Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005; 128:343–350. https://doi.org/10.1053/j.gastro.2004.11.018 PMID: 15685546

18. Masuzaki R, Tateishi R, Yoshida H, Goto E, Sato T, Ohki T, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology. 2009:1954–1961. https://doi.org/10.1002/hep.22870 PMID: 19434742

19. Lurie Y, Webb M, Cyrtter-Kuint R, Shteingart S, Lederkremer GZ. Non-invasive diagnosis of liver fibrosis and cirrhosis. World J Gastroenterol. 2015; 21:11567–11583. https://doi.org/10.3748/wjg.v21.i41.11567 PMID: 26556987
20. Sharma S, Khalili K, Nguyen GC. Non-invasive diagnosis of advanced fibrosis and cirrhosis. World J Gastroenterol. 2014; 20:16820–16830. https://doi.org/10.3748/wjg.v20.i45.16820 PMID: 25492996

21. Loomba R, Adams LA. Advances in non-invasive assessment of hepatic fibrosis. Gut. 2020; 69:1343–1352. https://doi.org/10.1136/gutjnl-2018-317593 PMID: 32066623

22. Zeuzem S, Foster GR, Wang S, Aasary A, Gane E, Feld JJ, et al. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med. 2018; 378:354–369. https://doi.org/10.1056/NEJMoa1702417 PMID: 29365309

23. Omata M, Nishiguchi S, Ueno Y, Mochizuki H, Izumi N, Ikeda F, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat. 2014; 21:762–768. https://doi.org/10.1111/j.vlh.12312 PMID: 25196837

24. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014; 370:1889–98. https://doi.org/10.1056/NEJMoa1402454 PMID: 24725239

25. Toyoda H, Atsukawa M, Uojima H, Nozaki A, Tamai H, Takaguchi K, et al. Trends and Efficacy of Interferon-Free Anti-hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10688 Patients in Japan. Open Forum Infect Dis. 2019; 15; 6:ofz185. https://doi.org/10.1093/ofid/ofz185 PMID: 31123693

26. Ikeda H, Watanabe T, Atsukawa M, Toyoda H, Takaguchi K, Nakamuta M, Takaguchi K, et al. Efficacy and safety of ombitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan. Hepatol Res. 2019; 49:369–376. https://doi.org/10.1111/hepr.13292 PMID: 30485638

27. Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, et al. Efficacy and safety of glecaprevir/pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study. Aliment Pharmacol Ther. 2019; 49:1230–1241. https://doi.org/10.1111/apt.15218 PMID: 30873651

28. Atsukawa M, Tsubota A, Kondo C, Toyoda H, Nakamuta M, Takaguchi K, et al. Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study. Infect Dis Ther. 2020; 9:851–866. https://doi.org/10.1007/s40121-020-00329-y PMID: 32897520

29. Ikeda H, Watanabe T, Atsukawa M, Toyoda H, Takaguchi K, Nakamuta M, et al. Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naive noncirrhotic HCV genotype 1 and 2 infected patients in a real-world setting in Japan. J Viral Hepat. 2019; 26:1269–1275. https://doi.org/10.1111/jvhl.14447 PMID: 30144366

30. Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, et al. Efficacy and safety of omibitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan. Hepatol Res. 2019; 49:369–376. https://doi.org/10.1111/hepr.13292 PMID: 30485638

31. Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, et al. The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study. Aliment Pharmacol Ther. 2019; 49:1230–1241. https://doi.org/10.1111/apt.15218 PMID: 30873651

32. European Association for the Study of the Liver, EASL recommendations on treatment of hepatitis C: Final update of the series. J Hepatol. 2020; 73:1170–1218. https://doi.org/10.1016/j.jhep.2020.08.018 PMID: 32956768

33. Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update. Hepatol Res. 2020; 50:791–816. https://doi.org/10.1111/hepr.13503 PMID: 32343777

34. Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, et al. APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int. 2016; 10:681–701. https://doi.org/10.1111/hepi.12702-016-9736-3 PMID: 27229718

35. El-Serag HB, Kanwal F, Richardson P, et al. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology. 2016; 64:130–137. https://doi.org/10.1002/hep.28535 PMID: 26946190

36. Ogawa E, Furusyo N, Nomura H, Dohmen K, Higashi N, Takahashi K, et al. Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment. Aliment Pharmacol Ther. 2018; 47:104–113. https://doi.org/10.1111/apt.14380 PMID: 29035002

37. Ioannou GN, Green PK, Beste LA, et al. Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C. J Hepatol. 2018; 69:1088–1098. https://doi.org/10.1016/j.jhep.2018.07.024 PMID: 30138686
38. Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017; 153:996–1005. e1. https://doi.org/10.1053/j.gastro.2017.06.012 PMID: 28642197

39. Tsubota A, Kumada H, Chayama K, Arase Y, Saitoh S, Koida I, et al. Time course of histological changes in patients with a sustained biochemical and virological response to interferon-alpha therapy for chronic hepatitis C virus infection. J Hepatol. 1997; 27:49–55. https://doi.org/10.1016/s0168-8278(97)80279-6 PMID: 9252073